Cargando…

Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity

Chemotherapeutic agents are generally used as a frontline therapy for non-small cell lung cancer (NSCLC). However, resistance to chemotherapy arises rapidly in NSCLC, and the reasons for chemotherapy resistance have not been fully determined. Here, we found cisplatin, but not paclitaxel and doxorubi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Lihui, Liu, Xing, Ren, Yong, Zhang, Jingyuan, Chen, Junli, Zhou, Wenlong, Guo, Wei, Wang, Xiaoxuan, Chen, Huiping, Li, Meng, Yuan, Xiangzhong, Zhang, Xun, Yang, Jingyu, Wu, Chunfu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477570/ https://www.ncbi.nlm.nih.gov/pubmed/28406482 http://dx.doi.org/10.1038/cddis.2016.409

Ejemplares similares

Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer
por: Wang, Wenjing, et al.
Publicado: (2020)

Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer
por: Li, Meng, et al.
Publicado: (2017)

TRIB2 contributes to cisplatin resistance in small cell lung cancer
por: Liang, Yuanxin, et al.
Publicado: (2017)

Targeting HDAC/OAZ1 axis with a novel inhibitor effectively reverses cisplatin resistance in non-small cell lung cancer
por: Sun, Yuhong, et al.
Publicado: (2019)

Targeting ALDH1A1 by disulfiram/copper complex inhibits non-small cell lung cancer recurrence driven by ALDH-positive cancer stem cells
por: Liu, Xinwei, et al.
Publicado: (2016)

Depletion of HDAC6 Enhances Cisplatin-Induced DNA Damage and Apoptosis in Non-Small Cell Lung Cancer Cells
por: Wang, Lei, et al.
Publicado: (2012)

Capsaicin-induced TRIB3 upregulation promotes apoptosis in cancer cells
por: Lin, Rong-Jaan, et al.
Publicado: (2018)

The Critical Role of TRIB2 in Cancer and Therapy Resistance
por: Mayoral-Varo, Victor, et al.
Publicado: (2021)

The Pseudokinase TRIB1 in Immune Cells and Associated Disorders
por: Danger, Richard, et al.
Publicado: (2022)

Regulation of TRIB3 mRNA and Protein in Breast Cancer
por: Wennemers, Marloes, et al.
Publicado: (2012)

The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53
por: Hu, Chen, et al.
Publicado: (2020)

Priming with HDAC Inhibitors Sensitizes Ovarian Cancer Cells to Treatment with Cisplatin and HSP90 Inhibitors
por: Rodrigues Moita, Ana J., et al.
Publicado: (2020)

TRIB2 safeguards naive T cell homeostasis during aging
por: Cao, Wenqiang, et al.
Publicado: (2023)

TRIB2 desensitizes ferroptosis via βTrCP-mediated TFRC ubiquitiantion in liver cancer cells
por: Guo, Susu, et al.
Publicado: (2021)

Genomic and Functional Regulation of TRIB1 Contributes to Prostate Cancer Pathogenesis
por: Shahrouzi, Parastoo, et al.
Publicado: (2020)

Liver cancer stem cells are selectively enriched by low-dose cisplatin
por: Zhang, H., et al.
Publicado: (2014)

TRIB2 modulates proteasome function to reduce ubiquitin stability and protect liver cancer cells against oxidative stress
por: Guo, Susu, et al.
Publicado: (2021)

Correction: TRIB2 desensitizes ferroptosis via βTrCP-mediated TFRC ubiquitiantion in liver cancer cells
por: Guo, Susu, et al.
Publicado: (2021)

Abnormal expression of TRIB3 in colorectal cancer: a novel marker for prognosis
por: Miyoshi, N, et al.
Publicado: (2009)

High glucose contributes to the proliferation and migration of non-small-cell lung cancer cells via GAS5-TRIB3 axis
por: Ding, Cheng-Zhi, et al.
Publicado: (2018)

Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines
por: Bandolik, Jan J., et al.
Publicado: (2019)

TRIB3 suppresses proliferation and invasion and promotes apoptosis of endometrial cancer cells by regulating the AKT signaling pathway
por: Qu, Junjie, et al.
Publicado: (2019)

Oncogenic TRIB2 interacts with and regulates PKM2 to promote aerobic glycolysis and lung cancer cell procession
por: Liu, Yuan-Rong, et al.
Publicado: (2022)

TRIB3 Modulates PPARγ-Mediated Growth Inhibition by Interfering with the MLL Complex in Breast Cancer Cells
por: Hernández-Quiles, Miguel, et al.
Publicado: (2022)

The CRISPR-Cas9 system: a promising tool for discovering potential approaches to overcome drug resistance in cancer
por: Zhang, Jiayu, et al.
Publicado: (2018)

Efficacy of HDAC Inhibitors Belinostat and Panobinostat against Cisplatin-Sensitive and Cisplatin-Resistant Testicular Germ Cell Tumors
por: Lobo, João, et al.
Publicado: (2020)

Trib2 regulates the pluripotency of embryonic stem cells and enhances reprogramming efficiency
por: Do, Eun Kyoung, et al.
Publicado: (2017)

TRIB3 facilitates glioblastoma progression via restraining autophagy
por: Tang, Zhanbin, et al.
Publicado: (2020)

The Involvement of TRIB3 and FABP1 and Their Potential Functions in the Dynamic Process of Gastric Cancer
por: Liu, Songyi, et al.
Publicado: (2021)

Role of TRIB3 in Diabetic and Overnutrition-Induced Atherosclerosis
por: Sowers, James R.
Publicado: (2012)

TRIB3-P62 interaction, diabetes and autophagy
por: Hua, Fang, et al.
Publicado: (2015)

Evidence for a role of TRIB3 in the regulation of megakaryocytopoiesis
por: Butcher, Lee, et al.
Publicado: (2017)

TRIB1 promotes colorectal cancer cell migration and invasion through activation MMP-2 via FAK/Src and ERK pathways
por: Wang, Yuhui, et al.
Publicado: (2017)

HDAC6 Regulates Radiosensitivity of Non-Small Cell Lung Cancer by Promoting Degradation of Chk1
por: Moses, Niko, et al.
Publicado: (2020)

Deletion of TRIB3 disrupts the tumor progression induced by integrin αvβ3 in lung cancer
por: Zhou, Wen, et al.
Publicado: (2022)

miR-99 inhibits cervical carcinoma cell proliferation by targeting TRIB2
por: XIN, JIA-XUAN, et al.
Publicado: (2013)

Trib1 regulates T cell differentiation during chronic infection by restraining the effector program
por: Rome, Kelly S., et al.
Publicado: (2020)

TRIB1 confers therapeutic resistance in GBM cells by activating the ERK and Akt pathways
por: Singh, Karnika, et al.
Publicado: (2023)

Targeting procaspase-3 with WF-208, a novel PAC-1 derivative, causes selective cancer cell apoptosis
por: Wang, Fangyang, et al.
Publicado: (2015)

TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target
por: Yu, Jiao-jiao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c724kc8jf5phmi8nil1s9mplni